Bianca Rocca: Evaluating Factor XI Inhibition Lessons from LIBREXIA-ACS
Bianca Rocca, Editor in Chief at European Heart Journal Cardiovascular Pharmacotherapy, shared a post on LinkedIn about a recent article by Renske H Olie et al, published in European Heart Journal – Cardiovascular Pharmacotherapy, adding:
“Does a negative trial close the chapter, or redefine the questions?
The editorial ‘The LIBREXIA-ACS trial: new fuel for debate?’ by Renske Olie, Jur ten Berg, and Hugo Ten cate, is an insightful and timely contribution to the ongoing discussion on Factor XI inhibition. Negative trials may be disappointing, but they often help shape unanswered questions and the development of antithrombotic strategies.”
Title: The LIBREXIA-ACS trial: new fuel for debate?
Authors: Renske H Olie, Jurrien ten Berg, Hugo ten Cate
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 12, 2026, 17:39Annie Bauzon: Differentiating Direct and Indirect Coombs Tests in Hematology
-
Oct 12, 2026, 17:15Cedric Hermans: Identifying and Diagnosing Hemophilia Carriers and Affected Females
-
Oct 12, 2026, 13:58Francisco Chacón-Lozsán: Catastrophic Antiphospholipid Syndrome A Rapidly Progressive Multiorgan Thrombotic Emergency
-
Oct 12, 2026, 12:50Nawsherwan Mohammad: Study Examines Thrombotic Events in Patients with Polycythemia Vera in Iraq
-
Oct 12, 2026, 12:30Chanakya Nayudu: Looking Beyond Blood Clots – Patient-Reported Outcomes in Antiphospholipid Syndrome
-
Oct 12, 2026, 12:12Jean-Jacques Kiladjian: Improving Treatment Strategies with JAK Inhibitors in Myelofibrosis
-
Oct 12, 2026, 12:04Chloe Homich: AABB Annual Meetings – Building Connections and Advancing Transfusion Medicine
-
Oct 12, 2026, 11:51Daniel Sop: Sickle Cell Research Takes Center Stage at ASCAT 2026
-
Oct 12, 2026, 10:36PAI-1 Inhibition as a New Strategy for Enhancing Fibrinolysis and Clot Resolution